A recent article published by TCTMD talks about increased diversity at #ACC17. “The biggest impact of ACC 2017 won’t come from a trial, a drug, or a device, but from the faces we saw in the Main Tent,” says the author of the article, Shelley Wood. “Each of the late-breaking clinical trial and featured clinical research sessions at ACC 2017 had at least one woman, usually two, among the...
View details ⇨

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

ow.ly
FITs: Looking for a recap of #ACC17? Check out the FITsontheGO video blog for full video coverage of #ACC17, including interviews on the results of the hottest trials, tips for using social media, and more: [ Ow.ly Link ] Get more ACC.17 coverage on ACC.org/ACC2017.

ACC.17 - YouTube

youtube.com
Leadership Academy Meeting
ECG of the Month: A 54-year old-woman with a history of myelodysplastic disease presents after radiation therapy for follicular lymphoma. She is awaiting stem cell transplant and is bothered by palpitations and weak spells. Her echocardiogram shows normal ventricular function. Read more and test your knowledge: [ Ow.ly Link ]

ECG of the Month: Patient Awaiting Stem Cell Transplant Presents With...

ow.ly
Watch the new ACC Cardiology Hour, an expert roundtable discussion of late-breaking clinical trials from #ACC17. Valentin Fuster, MD, PhD, MACC, hosts Deepak L. Bhatt, MD, MPH, FACC; Anne B. Curtis, MD, FACC; Kim A. Eagle, MD, MACC; Michael J. Mack, MD, FACC; and Donna M. Mancini, MD, in a lively discussion on FOURIER, SPIRE 1 and SPIRE 2, EBBINGHAUS, SURTAVI, IFR-SWEDEHEART, and more. See the...
View details ⇨

New Expert Roundtable on Hot Trials From ACC.17

ow.ly
Save the Date for ACC's 67th Annual Scientific Session & Expo (#ACC18) in Orlando, Florida, taking place Saturday, March 10 – Monday, March 12, 2018! Mark Your Calendar with these key dates: Abstract & Case Submissions ~ Tuesday, Aug. 22 – Tuesday, Oct. 10, 2017; Late-Breaking Clinical Trial Submissions ~ Wednesday, Oct. 18 – Wednesday, Dec. 6, 2017. Check back in August for additional...
View details ⇨
The complete 30- and 90-day results of LEVO-CTS, a large randomized multicenter clinical trial, provides insight into the efficacy and safety of levosimendan in reducing short-term morbidity and mortality in high-risk patients undergoing cardiac surgery with CPB. Visit ACC.org/ACC2017 for full #ACC17 coverage: [ Youtube.com Link ]

LEVO-CTS

The complete 30- and 90-day results of LEVO-CTS, a large randomized multicenter clinical trial, will provide insight into the efficacy and safety of levosime...

YOUTUBE.COM
Medical professionals from all over the world traveled to Washington, DC, for ACC’s 66th Annual Scientific Session and Expo (ACC.17). Complete meeting coverage from ACC.17 is available at ACC.org/ACC2017 and on Twitter (@ACCCardioEd, #ACC17).
Read in-depth coverage from Reuters of the #ACC17 CVD-REAL Study: [ Ow.ly Link ]

Newer type 2 diabetes drugs show heart protective quality in study

ow.ly
Check out the FITsontheGo video blog for full #ACCFIT video coverage of #ACC17, including discussions of the results of the hottest trials, tips for using social media, and more: [ Youtube.com Link ]

FITsontheGO Video Coverage of ACC.17

youtube.com
Two different embolic protection devices were successful in capturing debris during surgical aortic valve replacement but did not significantly reduce the overall number of brain infarcts compared with the standard surgical procedure, according to research presented March 19 at #ACC17 in Washington, DC. The study was terminated early after an interim analysis concluded that it was not likely...
View details ⇨

Cerebral Embolic Protection During SAVR Reduced Size, But Not Number of...

ow.ly
Clinical benefit including increased cardiac output was gained with the calcium-sensitizing inotrope levosimendan, although the co-primary endpoints were not significantly improved in the LEVO-CTS trial evaluating the effect of the drug to prevent low cardiac output syndrome (LCOS) and its associated adverse outcomes in patients with a low left ventricular ejection fraction undergoing cardiac...
View details ⇨

LEVO-CTS: No Improvement in Primary Outcomes With Levosimendan For...

ow.ly
Half of the multi-vessel STEMI patients have no hemodynamic important non-culprit lesions by FFR. Whether FFR-CR is superior to CLO treatment strategy is discussed. Visit ACC.org/ACC2017 for full #ACC17 coverage: [ Youtube.com Link ]

COMPARE-ACUTE

YOUTUBE.COM
Check out in-depth coverage from TIME of the #ACC17 trial covering CAD levels in Native South American Tsimanes: [ Ow.ly Link ]

This Is the Secret to Not Getting Heart Disease

ow.ly
The #ACCFITJeopardy Battle Continues at #ACC17! Watch the Texas Chapter and the Florida Chapter compete for the championship and cheer on your favorite team!
Extended treatment with low-dose rivaroxaban provided nearly a three-fold greater reduction in recurrent venous thromboembolism than aspirin with a similar rate of bleeding in patients who had completed six to 12 months of anticoagulation, according to the results pf the EINSTEIN CHOICE Trial presented by Phil S. Wells, MD, on March 18 at #ACC17 in Washington, DC, and simultaneously published...
View details ⇨

Low-Dose Rivaroxaban vs. Aspirin Reduces Recurrent VTE in EINSTEIN CHOICE

ow.ly
In the largest study to address the question to date, researchers found no evidence that adding the #PCSK9 inhibitor evolocumab on top of statin treatment causes memory loss or other cognitive issues, according to the EBBINGHAUS Trial presented by Robert P. Giugliano, MD, SM, FACC, on March 18 at #ACC17 in Washington, DC: [ Ow.ly Link ]

EBBINGHAUS: No Effect on Neurocognition With Evolucumab

ow.ly
ORION-1 will provide information from 6 through 9 months on the potential for inclisiran to deliver sustained reductions in LDL-C either as a biannual or quarterly regimen safely and identify the dose and dosing regimen to be used in future Phase 3 CVOTs. Visit ACC.org/ACC2017 for full #ACC17 coverage: [ Youtube.com Link ]

Video Coverage of ORION-1 Trial From ACC.17

YOUTUBE.COM